Capricor shares plunge 64% after FDA disclosures on Deramiocel
AI Summary- Robbins LLP filed a securities class action against Capricor Therapeutics over Deramiocel disclosures.
- Capricor shares fell 64% to $7.00 after FDA disclosures on July 27, 2026.
- Investors seeking lead-plaintiff appointment must act before September 28, 2026.